Home / Market News / $TRAX

$TRAX news and market catalysts

The 22 most recent market catalysts affecting $TRAX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

22 catalysts 2 high impact 17 bullish 0 bearish Biotechnology
Nov 4, 2026 Corporate Catalyst Bullish Impact 65
Guggenheim Maintains Buy Rating and Raises Price Target for First Tracks Biotherapeutics
Guggenheim's reaffirmation of a 'Buy' rating and a price target increase for First Tracks Biotherapeutics (TRAX) from $100 to $110 is a positive signal for the company. This action…
Oct 16, 2026 Corporate Catalyst Bullish Impact 60
Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90
Leerink Partners analyst David Risinger maintained an 'Outperform' rating on First Tracks (TRAX) and raised the price target from $70 to $90. This analyst upgrade and increased pri…
Oct 15, 2026 Corporate Catalyst Neutral Impact 75
First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors
First Tracks Biotherapeutics secured a substantial $200 million through a private placement, selling shares to a group of institutional investors. This capital infusion is crucial …
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60
Canaccord Genuity analyst Edward Nash has maintained a 'Buy' rating on First Tracks (TRAX) and raised the price target from $50 to $60. This action signals a positive outlook from …
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Group Maintains Outperform on First Tracks, Raises Price Target to $70
Evercore ISI Group analyst Gavin Clark-Gartner has maintained an 'Outperform' rating on First Tracks (TRAX) and raised the price target from $65 to $70. This action signals continu…
Oct 13, 2026 Corporate Catalyst Bullish Impact 65
Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $70
Wells Fargo analyst Derek Archila maintained an 'Overweight' rating on First Tracks (TRAX) and raised the price target from $62 to $70. This action signals increased confidence fro…
Oct 12, 2026 Corporate Catalyst Bullish Impact 75
First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday
The primary catalyst in this filing is First Tracks Biotherapeutics' positive Phase 1b clinical trial results for ANB033 in celiac disease. This is a significant event for the comp…
Oct 12, 2026 Corporate Catalyst Bullish Impact 85
First Tracks Biotherapeutics' ANB033 Demonstrates Statistically Significant Histologic And Symptom Benefits In Phase 1b Celiac Disease Trial
First Tracks Biotherapeutics (TRAX) has reported highly positive Phase 1b trial results for ANB033 in celiac disease, showing statistically significant and clinically meaningful pr…
Sep 30, 2026 Corporate Catalyst Neutral Impact 65
Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50
Canaccord Genuity analyst Edward Nash has initiated coverage on First Tracks (TRAX) with a 'Buy' rating and a $50 price target. This event is significant because new analyst covera…
Sep 18, 2026 Corporate Catalyst Neutral Impact 65
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
The filing details the initiation of analyst coverage for five companies: First Tracks Biotherapeutics (TRAX), Boyd Group Services (BGSI), Neuropace Inc (NPCE), Cue Biopharma Inc (…
Sep 18, 2026 Corporate Catalyst Neutral Impact 65
Evercore ISI Group Initiates Coverage On First Tracks with Outperform Rating, Announces Price Target of $65
Evercore ISI Group has initiated coverage on First Tracks (TRAX) with an 'Outperform' rating and a $65 price target. This is significant because new analyst coverage, especially wi…
Sep 16, 2026 Corporate Catalyst Neutral Impact 65
Guggenheim Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $100
Guggenheim analyst Yatin Suneja initiated coverage on First Tracks (TRAX) with a 'Buy' rating and a $100 price target. This event is significant for TRAX as new analyst coverage, e…
Aug 13, 2026 Corporate Catalyst Bullish Impact 60
Barclays Maintains Overweight on First Tracks, Raises Price Target to $65
Barclays analyst Etzer Darout maintained an 'Overweight' rating on First Tracks (TRAX) and raised the price target from $48 to $65. This substantial increase in the price target, r…
Aug 13, 2026 Corporate Catalyst Bullish Impact 75
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
First Tracks Biotherapeutics (TRAX) announced a Q2 loss of 95 cents per share, which is a significant improvement from the $1.47 loss in the year-ago period. This narrower loss, co…
Aug 13, 2026 Corporate Catalyst Bullish Impact 65
Wedbush Maintains Outperform on First Tracks, Raises Price Target to $70
Wedbush analyst Martin Fan has maintained an 'Outperform' rating on First Tracks (TRAX) and raised the price target from $60 to $70. This positive analyst action signals increased …
Aug 13, 2026 Corporate Catalyst Bullish Impact 65
Piper Sandler Maintains Overweight on First Tracks, Raises Price Target to $95
Piper Sandler analyst Yasmeen Rahimi maintained an 'Overweight' rating on First Tracks (TRAX) and raised the price target from $54 to $95. This significant increase in the price ta…
Aug 13, 2026 Corporate Catalyst Bullish Impact 65
HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $57
HC Wainwright & Co. analyst Emily Bodnar maintained a 'Buy' rating on First Tracks and significantly raised the price target from $44 to $57. This upgrade indicates a strong belief…
Aug 12, 2026 Corporate Catalyst Bullish Impact 85
First Tracks Q2 EPS $(0.95) Up From $(1.47) YoY
First Tracks (TRAX) announced its Q2 earnings, reporting a loss of $(0.95) per share, which is a substantial improvement from the $(1.47) loss per share in the same period last yea…
Aug 10, 2026 Corporate Catalyst Bullish Impact 60
UBS Maintains Buy on First Tracks, Raises Price Target to $65
UBS analyst Michael Yee maintained a 'Buy' rating on First Tracks (TRAX) and raised the price target from $45 to $65. This substantial increase in the price target, representing a …
Jul 28, 2026 Corporate Catalyst Bullish Impact 75
Wedbush Maintains Outperform on First Tracks, Raises Price Target to $60
Wedbush analyst Martin Fan maintained an 'Outperform' rating on First Tracks (TRAX) and dramatically raised the price target from $30 to $60. This action signals a strong vote of c…
Jul 28, 2026 Market Technicals Bullish Impact 55
Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $55
Wells Fargo analyst Derek Archila has raised the price target for First Tracks (TRAX) from $30 to $55 while maintaining an Overweight rating. This substantial increase in the price…
Jul 21, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Overweight on First Tracks, Raises Price Target to $48
Barclays analyst Etzer Darout has maintained an 'Overweight' rating on First Tracks and raised the price target from $40 to $48. This action signals increased confidence from a maj…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.